KCNMB1 and Hypertension: An in vivo model of gestational hypertension in rats revealed that DMF oral treatment (25 mg/kg) decreases mRNA and protein levels of ten-eleven translocation 1 (TET1) and calcium-activated potassium channel subunit β1 (KCNMB1) (Zhou et al., 2021); TET1 is upregulated by estrogen during pregnancy and increases KCNMB1 level, which is associated with hypertension (Han et al., 2017).